The 3 Biggest Risks for Pfizer in 2017

Pfizer (NYSE:PFE) appears to be on track to end 2016 with its stock price at roughly the same level as it began the year. Could the new year present better opportunities for the big pharma? Yes, but challenges remain. Here are three of Pfizer’s biggest risks in 2017.

MORE ON THIS TOPIC